Dr. Reddy’s Laboratories launches Semaglutide injection ‘Obeda’ for Type 2 Diabetes

Dr. Reddy's Laboratories has launched its injectable semaglutide under the brand name Obeda, marking an important step in expanding access to advanced GLP 1 receptor agonist-based therapy for the management of type 2 diabetes in India. The company has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. This launch underscores the company’s Day 1 entry into the segment upon patent expiry, demonstrating its readiness to serve unmet patient needs in India. The company’s Obeda injection is available in 2 mg and 4 mg strengths and comes in a pre- filled, disposable pen designed for subcutaneous, once a-week administration, with robust cold chain integrity maintained throughout distribution. Each pen of both strengths will deliver a minimum of 4 weekly doses. The cost to the patient will be Rs 4,200 per month for both the strengths. Additionally, in a human factors study involving 41 participants completing around 20 key tasks aligned with the USFDA’s guidance for drug-device combination products, the Obeda pen demonstrated non inferior user performance outcomes compared with the innovator pen.